November 18, 2011

Terminal Complement Inhibition Decreases Antibody-Mediated Rejection in Sensitized Renal Transplant Recipients


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

There has been much interest in transplantation around eculizumab, a monoclonal antibody that blocks formation of the membrane attack complex of the complement cascade. In this single-centre, non-randomized study, patients with donor-specific antibody who were treated with eculizumab had a significantly lower rate of antibody-mediated rejection that a group of historical controls. There was also a lower rate of transplant glomerulopathy in the eculizumab-treated patients.

Renal Transplantation

Tags: , , , ,